RESEARCH ARTICLE

Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada

Thomas E. Delea1, Derek Weycker1, Mark Atwood1, Dion Neame2, Fabián P. Alvarez3, Evelyn Forget4, Joanne M. Langley5, Ayman Chit6,7

1 Policy Analysis Inc. (PAI), Brookline, MA, United States of America, 2 Sanofi Pasteur, Toronto, ON, Canada, 3 Sanofi Pasteur, Lyon, France, 4 Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, 5 Canadian Center for Vaccinology and the Departments of Pediatrics and Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada, 6 Sanofi Pasteur, Swiftwater, PA, United States of America, 7 Lesli Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

* tdelea@pai2.com

Abstract

Background
Public health programs to prevent invasive meningococcal disease (IMD) with monovalent serogroup C meningococcal conjugate vaccine (MCV-C) and quadrivalent meningococcal conjugate vaccines (MCV-4) in infancy and adolescence vary across Canadian provinces. This study evaluated the cost-effectiveness of various vaccination strategies against IMD using current and anticipated future pricing and recent epidemiology.

Methods
A cohort model was developed to estimate the clinical burden and costs (CAN$2014) of IMD in the Canadian population over a 100-year time horizon for three strategies: (1) MCV-C in infants and adolescents (MCV-C/C); (2) MCV-C in infants and MCV-4 in adolescents (MCV-C/4); and (3) MCV-4 in infants (2 doses) and adolescents (MCV-4/4). The source for IMD incidence was Canadian surveillance data. The effectiveness of MCV-C was based on published literature. The effectiveness of MCV-4 against all vaccination regimens was assumed to be the same as for MCV-C regimens against serogroup C. Herd effects were estimated by calibration to estimates reported in prior analyses. Costs were from published sources. Vaccines prices were projected to decline over time reflecting historical procurement trends.

Results
Over the modeling horizon there are a projected 11,438 IMD cases and 1,195 IMD deaths with MCV-C/C; expected total costs are $597.5 million. MCV-C/4 is projected to reduce cases of IMD by 1,826 (16%) and IMD deaths by 161 (13%). Vaccination costs are
Cost-effectiveness of IMD immunization in Canada

Vaccinology at Dalhousie University, Halifax, Canada. Sanofi Pasteur was provided a review of the study research plan and study manuscript; model development and estimation, analyses, and all final decisions related to analytics and the manuscript were made by study authors. Policy Analysis Inc. (PAI) provided support in the form of salaries for authors TED, DW and MA, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. Sanofi Pasteur provided support in the form of salaries for authors DN, FPA and AC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

Competing interests: Funding for this research was provided by Sanofi Pasteur to Policy Analysis Inc. (PAI). Mark Atwood, Thomas Delea, and Derek Weycker are employed by PAI. Ayman Chit, Dion Neame, and Fabián Alvarez are employed by Sanofi Pasteur. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Increased by $32 million but direct and indirect IMD costs are projected to be reduced by $46 million. MCV-C/4 is therefore dominant vs. MCV-C/C in the base case. Cost-effectiveness of MCV-4/4 was $111,286 per QALY gained versus MCV-C/4 (2575/206 IMD cases/deaths prevented; incremental costs $68 million).

Conclusions

If historical trends in Canadian vaccines prices continue, use of MCV-4 instead of MCV-C in adolescents may be cost-effective. From an economic perspective, switching to MCV-4 as the adolescent booster should be considered.

Introduction

Invasive meningococcal disease (IMD) is a life-threatening illness caused by the bacterium *Neisseria meningitidis*, and occurs when bacteria spread to the meninges (the membranes enveloping the central nervous system), the bloodstream, or both. Case fatality rates are about 10% even with early acute care, and survivors may suffer severe and permanent disabilities [1].

As in most developed countries, IMD is uncommon in Canada. Between 2001 and 2005, almost all Canadian provinces and territories except Nunavut introduced monovalent conjugate meningococcal vaccines against serogroup C (MCV-C) into the routine immunization schedule. The use of these vaccines has helped control illness due to that serogroup [2]. Serogroup B accounted for 55% of all cases during the 2002–2011 period, with serogroups C (19%), Y (17%), and W-135 (5%) occurring at lower frequencies[3]. The annual incidence of IMD in all Canadians was 0.6 per 100,000 during 2005–2010, and was highest among children aged <5 years (7.0 and 1.8 per 100,000 children aged <1 and 1–4 years, respectively) and adolescents (1.2 per 100,000 children aged 15–19 years) [4].

In Canada, three MCV-C and three quadrivalent meningococcal conjugate vaccines against serogroups A, C, Y, and W-135 (MCV-4) are available [5]. A vaccine for meningococcal B disease also has been approved. The Canadian National Advisory Committee on Immunization (NACI) recommends that healthy children be immunized with MCV-C routinely at 12 months of age and a routine adolescent booster dose at around 12 years of age with either MCV-C or MCV-4, depending on local epidemiology and other programmatic considerations [6]. All provinces and territories offer infant MCV-C programs and a booster dose in adolescence. Seven of the authorities use MCV-C in their public programs for adolescents and the remaining six use MCV-4 [4]. No jurisdiction has incorporated vaccination against meningococcal B disease in its routine programs.

De Wals and colleagues evaluated the cost-effectiveness of adolescent vaccination against IMD with MCV-C or MCV-4 in Canada in 2007 [7]. Results of that study suggested that adolescent vaccination with MCV-C may be cost-saving and that adolescent vaccination with MCV-4 may be cost-effective compared with adolescent vaccination with MCV-C. However, the vaccine prices that were used in this study are now a decade old, and costs of vaccines against meningococcal disease in Canada have declined over time, likely as a consequence of the tender process by which vaccines are purchased by the provinces. Further, guidelines for the economic evaluation of health technologies suggest that it may be appropriate to account for anticipated future changes in drug prices in these evaluations [8]. This study was undertaken to determine if there is an incremental value of MCV-4 vs MCV-C by estimating the cost-effectiveness of MCV-4 vs MCV-C for the infant and/or adolescent dose in Canada, using
recent epidemiologic and vaccine pricing data, and incorporating projections of future vaccine prices based on observed historical trends.

**Materials and methods**

**Model description**

A multi-cohort Markov model was developed in Microsoft Excel to estimate the expected clinical and economic impact of vaccination against IMD in a hypothetical prevalent cohort of 33.3 million Canadian population and subsequent birth cohorts of 385 thousand newborns each year over a 100 year time horizon. Vaccine strategies considered in this analysis included (1) MCV-C vaccination in infants (12 months) and adolescents (13 years) (MCV-C/C); (2) MCV-C vaccination in infants and MCV-4 vaccination in adolescents (MCV-C/4); and (3) MCV-4 vaccination in infants and adolescents (MCV-4/4). In Canada, three MCV-4 vaccines are available (Menactra [Sanofi Pasteur Ltd.], Menveo [Novartis Vaccines and Diagnostics Inc.], Nimenrix [GlaxoSmithKline]), although only two (Menactra and Menveo) are being used in public health programs at the time of this analysis (Nimenrix did not win any market share on the Canadian tender despite it being available). This analysis uses effectiveness information for Menactra, under the assumption it would be similar for Menveo.

The population is characterized based on age (in one-month increments for persons aged <2 years, and one-year increments thereafter) [9]. In each cycle, the model projects the number of IMD cases by serogroup based on population size, age- and serogroup-specific disease rates, vaccine coverage, and vaccine effectiveness (including direct and indirect or “herd” effects). For persons developing IMD, the model projects the clinical consequences of IMD in terms of deaths and long-term sequelae [7, 10, 11]. All persons are assigned age-specific utility values. Those developing sequelae are assumed to have lower health-state utilities than those who do not.

The reduction in risk of infection in vaccinated persons (i.e., direct effects) is assumed to depend on the vaccine received (MCV-C or MCV-4), age at immunization, and time since immunization. ISPOR-SMDM Modeling Good Research Practices recommend the use of dynamic transmission models to estimate indirect effects where vaccination may effect transmission of the disease[12]. In the model, indirect effects for vaccinated and unvaccinated persons are estimated using an adaptation of a mathematical approximation of dynamic transmission modeling for use in cohort models [13, 14]. With this approach, the infection rate in each year of the projection for all age-groups \( i = 1 \) to \( N \) is multiplied by a scaling factor \( s \) that is calculated as follows:

\[
s = \sum_{i=1}^{N} (1 - P_i e_i) w_i
\]

Where \( P_i \) is the percent of persons in each age group who are vaccinated, \( e_i \) is the effectiveness of the vaccine in each group (reflecting the direct effects of vaccination and vaccine coverage), and \( w_i \) is a weight reflecting the percent of the entire cohort within each age group. The scalar for the herd effect was calibrated so that indirect effects in the model would approximately match those reported in the aforementioned economic evaluation of MCV-4 vaccination in Quebec by De Wals [7]. In this study, De Wals reported the numbers of cases with no vaccination, as well as the reduction in cases due to direct and indirect effects associated with MCV-C/C and MCV-C/4 vaccination. De Wals did not report results by age, so calibration was conducted for the overall population. We estimated the scalar for the herd effect by setting all model inputs to match those employed by De Wals, then solving for the value of the
parameter that yielded an estimate of the number of residual cases with MCV-C/4 vaccination that matched that reported by De Wals (0.90 per million). This calibration model yielded a projection of the percentage reduction in incidence due to direct and herd effects for MCV-C/4 vs. MCV-C/C that is somewhat greater than that reported by De Wals (58% vs. 50%). However, the percent of the total reduction in incidence due to herd effects was less with our model than reported by De Wals (71% vs. 85%).

For each vaccine strategy, the model was used to calculate the number of IMD clinical cases, case fatalities, non-fatal cases developing sequelae, life years (LYs) and quality-adjusted life years (QALYs) lost due to IMD, as well as the expected costs of vaccination (vaccine, administration, adverse events), public health response, and the total direct and indirect costs of treatment of IMD. Future costs and health benefits were discounted at 5% annually [8]. A societal perspective was employed.

Model estimation

Model parameters were estimated from a variety of sources and are described below and summarized in Table 1.

IMD rates. Age- and serogroup-specific rates of IMD for unvaccinated persons, assuming no herd effects from MCV-4 vaccination, were estimated by combining data on the number of IMD cases in Canada from the National Enhanced IMD Surveillance System [15], with unpublished data on the distributions of IMD cases by age and serogroup from Canada’s Immunization Monitoring Program ACTive (IMPACT) Network, and age-specific population estimates [9]. Because the focus of the present study is on the incremental impact of using MCV-4 in place of MCV-C, data on the number of cases were limited to the 3-year period prior to widespread use of MCV-4 (i.e., 2007–2009). From point estimates derived using these sources, linear interpolation and extrapolation was used to project values for all ages in monthly increments until the age of 2 years, and annually thereafter. Cases with an unknown serogroup were allocated proportionally across those with known serogroups. Estimated IMD rates were adjusted upward by 10% to account for potential under-reporting of IMD cases [16], but no upward adjustment was made for potential under-diagnosis of IMD as was done in the cost-effectiveness analysis by De Wals and colleagues [7]. Disease due to serogroup A was not included as no cases were reported during the surveillance period. Further details on these calculations may be found in the online supplement.

IMD case-fatality and sequelae rates. Age- and serogroup-specific IMD case-fatality rates were based on unpublished data from the IMPACT Network. The rate of sequelae among children surviving the initial event (13%) was based on the incidence of ≥1 long-term sequelae—including skin scarring, amputation, hearing loss, neurologic disability—among 136 children in Arkansas aged <21 years who developed IMD and survived the initial acute phase [17]. For adults, the rate of sequelae (20%) was based on the incidence of permanent physical sequelae—including amputation, hearing loss, and skin scarring—in a study of complications of IMD in college students in Allegheny County, Pennsylvania, from 1990 to 1999 [18]. These rates are consistent with those used in the cost-effectiveness analysis by De Wals and colleagues [7], as well as analyses by Caro and colleagues [19].

Vaccine effectiveness. MCV-C effectiveness in the first year following immunization for infants (91.7%) was based on data for children aged 1 year during the 2 years post-vaccination following an outbreak of serogroup C meningococcal disease and the subsequent implementation of a routine immunization program in Quebec, Canada [20]. Because this study did not report effectiveness for adolescents (only for children ≥2 years of age at vaccination), effectiveness for adolescents (93%) was based on the assumed effectiveness used in a cost-effectiveness
Table 1. Key model parameter values.

| Parameter | Age (Years) | Distribution | Sources |
|-----------|-------------|--------------|---------|
|           | <1 | 1 | 2–4 | 5–17 | ≥18 | |
| No. of Persons | 384,282 | 384,282 | 1,152,847 | 5,060,115 | 28,169,866 | N/A |
| IMD case rates by serogroup, per 100K | | | | |
| C | 1.306 | 0.56 | 0.143 | 0.13 | 0.065 | Beta |
| Y | 1.903 | 0.815 | 0.208 | 0.19 | 0.094 | Beta |
| W135 | 0.718 | 0.308 | 0.079 | 0.072 | 0.036 | Beta |
| IMD case-fatality rates by serogroup, per 100 | | | | |
| C | 6.3 | 6.3 | 6.3 | 6.3 | 15.4 | Beta |
| Y | 5.5 | 5.5 | 5.5 | 5.5 | 11.4 | Beta |
| W135 | 4 | 4 | 4 | 4 | 14.7 | Beta |
| Sequelae rates, per 100* | 13.2 | 13.2 | 13.2 | 13.2 | 20 | Uniform |
| Vaccine coverage, % | — | 91 | — | 84 | — | N/A |
| Vaccine effectiveness, 1 yr. post-receipt, % | | | | |
| MCV-C | 91.7 | 91.7 | 93.0** | 93 | Uniform |
| MCV-4 | 91.7 | 91.7 | 93.0** | 93 | Uniform |
| Vaccine waning, annual, % | | | | |
| MCV-C | 7.93 | 7.93 | 13.66 | 13.66 | Uniform |
| MCV-4 | 7.93 | 7.93 | 13.66 | 13.66 | Uniform |
| Utilities | | | | |
| Age-specific values | 0.98 | 0.98 | 0.98–0.96 | 0.96–0.59 | Uniform |
| Disutility from sequelae | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | Uniform |
| Direct medical and indirect costs, CAN$ | | | | |
| Vaccine | | | | |
| Price per dose, initial*** | | | | |
| MCV-4 | 31.42 | 31.42 | 31.42 | 31.42 | N/A |
| MCV-C | 13.12 | 13.12 | 13.12 | 13.12 | N/A |
| Administration, per dose | 5.07 | 5.07 | 5.07 | 11.5 | N/A |
| Adverse events, per dose | 0.07 | 0.07 | 0.07 | 0.07 | N/A |
| Direct Medical | | | | |
| IMD, per case | 14,144 | 14,144 | 14,144 | 14,144 | Uniform |
| Public health response | 4,250 | 4,250 | 4,250 | 4,250 | Uniform |
| Sequelae, annual, per case | 19,124 | 19,124 | 19,124 | 19,124 | Uniform |
| Indirect | | | | |
| Short-term indirect costs, per case | 3,047 | 3,047 | 3,047 | 3,047 | Uniform |
| Workforce participation, % | 0 | 0 | 0 | 13.2 | 66 | N/A |
| Average wage, annual | 0 | 0 | 0 | 3,494 | 46,171 | N/A |
| Productivity loss from sequelae, % | 46.8 | 46.8 | 46.8 | 46.8 | 68.4 | Uniform |

N/A: not applicable; IMD: invasive meningococcal disease; MCV-C: meningococcal conjugate vaccine—serogroup C; MCV-4: meningococcal conjugate vaccine—quadrivalent (serogroups A, C, Y, W135)

*Sequelae include skin scarring, single/multiple amputation, hearing loss, neurologic disability; rate per 100 IMD survivors

**Higher effectiveness assumed for adolescents

***The price of MCV-4 assumed to remain constant at $31.42 through 2016 and decline at 15.6% annually thereafter. The price of MCV-C assumed to remain constant at $13.12 through 2015 and decline at 10.0% annually thereafter.

All costs and benefits discounted at 5% annually

https://doi.org/10.1371/journal.pone.0175721.t001
analysis (CEA) reported by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) in their recommendations for the prevention and control of meningococcal disease [21]. Because data on effectiveness of MCV-4 in Canada were unavailable at the time this analysis was conducted, effectiveness of MCV-4 against all serogroups was assumed to be the same as for MCV-C, consistent with the approach used by De Wals and colleagues [7].

Vaccine effectiveness was assumed to wane over time (Fig 1). For infants, waning was estimated to be 7.93% annually by fitting an exponential distribution to the point estimates for children aged 1 year (66.7% [-38 to 92]) and children aged ≥2 years (87.8% [67.3 to 95.4]), respectively, during the period ≥2 years from vaccination in the Quebec study [20]. Waning for adolescents was estimated to be 13.66% annually by fitting an exponential curve to immunogenicity point estimates ≥2 years post vaccination reported by the ACIP [21]. Coverage with MCV-C or MCV-4 was assumed to be 91% among infants (age = 12 months) and 84% among adolescents (age = 13 years) [22].

**Vaccine costs.** In Canada, the public (federal/provincial/territorial) bulk procurement program purchases vaccines through a national tender that is renewed every 3 years. The costs of vaccines to the program have declined over time (Unpublished data. Public Health Agency of Canada) (Fig 2). To reflect the likely continuation of this trend during the projection period, vaccine prices in each year of the projection were estimated by fitting exponential curves to historical data on vaccine prices in past tender allocations. Because tenders typically last 2–3 years, the price of MCV-4 was assumed to remain constant at its current price ($31.42) through 2016 and decline (based on the exponential projection) at 15.6%

![Fig 1. Vaccine effectiveness by age.](https://doi.org/10.1371/journal.pone.0175721.g001)
annually thereafter. The price of MCV-C was assumed to remain constant at its current price ($13.12) through 2015 and decline (based on the exponential projection) at 10.0% annually thereafter. The price of MCV-4 was assumed to not fall below that of MCV-C. Costs of vaccine administration and vaccine-related adverse events were based on data from De Wals et al. [7]. For costing purposes, it was assumed that two doses of MCV-4 would be required to confer protection of infants, consistent with dosing recommendations for Menactra and Menveo in unvaccinated children 9–23 and 7–23 months of age, respectively [23, 24].

**Direct and indirect costs of IMD.** The direct medical costs of treating IMD and the sequelae of IMD were based on data from De Wals et al. [7]. The cost of public health response was based on a US cost-effectiveness analysis of meningococcal vaccination [10]. Costs in US dollars were converted to Canadian dollars based on health-related purchasing power parity [25]. Indirect costs—including those for morbidity-related work loss from IMD and sequelae of IMD, and mortality-related work loss from premature death—were estimated using a human-capital approach based on Canadian labor force survey estimates and census data and estimates of productivity loss from published literature [7]. All costs were adjusted to 2014 Canadian dollars [26].

**Utility values.** QALYs were calculated by combining estimates of life expectancy and the incidence of IMD sequelae with utility values. Utility values (QALY weights) are cardinal values anchored on 1.0 for perfect health and 0.0 for death that represent individuals’ preferences for different health outcomes. Age-specific utility values were from a prior study of the cost-effectiveness of IMD vaccination in the United States [19]. Decrements in utility values associated with IMD sequelae were based on EuroQol (EQ-5D) utility index values from the aforementioned study of complications of IMD in college students in Allegheny County, Pennsylvania [18].
Analyses

**Base-case analyses.** For each comparison (MCV-C/4 vs. MCV-C/C, MCV-4/4 vs. MCV-C/C, and MCV-4/4 vs. MCV-C/4), the differences in clinical and economic outcomes were calculated using base-case estimates of model inputs. Cost-effectiveness for each comparison was calculated in terms of cost per LY gained and cost per QALY gained. Strategies with lower costs and greater effectiveness were considered "dominant". When assessing whether a vaccination strategy was cost-effective, threshold values of $56,000 and $168,000 per QALY gained were used, which correspond to threshold values for "highly cost-effective" (<gross domestic product [GDP] per capita) and cost effective (<3 times GDP per capita), respectively, in the World Health Organization CHOosing Interventions that are Cost-Effective (WHO-CHOICE) guidelines [27, 28].

**Sensitivity analyses.** One-way deterministic sensitivity analyses were conducted to assess the robustness of findings with respect to clinically and economically reasonable changes in key parameter estimates. Probabilistic sensitivity analyses accounting for uncertainty surrounding key model parameters (1,000 replications) were used to generate credible intervals (95%) for measures of interest as well as scatter plots for incremental costs and QALYs and acceptability curves.

Results

**Base-case analyses**

Assuming MCV-C vaccination in infants and adolescents, the annual incidence of IMD in Canada is projected to be approximately 0.39 per 100,000 persons annually throughout the projection period, reflecting no change in the current vaccination program. With MCV-C vaccination in infants and MCV-4 vaccination in adolescents, incidence is projected to decline asymptotically from 0.39 per 100,000 in year 1 to approximately 0.25 per 100,000 in year 30 (after which it remains relatively constant). With MCV-4 vaccination in both infants and adolescents, incidence declines asymptotically to approximately 0.16 per 100,000 in year 50. The projected gradual decline in incidence with the MCV-4 vaccination programs reflects both the increasing proportion of persons in the population who are vaccinated as well as the increasing effects of herd immunity.

Over the 100 year projection period, assuming MCV-C vaccination in infants and adolescents, there would be a total of 11,438 IMD cases, 1,715 cases of IMD sequelae, and 1,195 IMD deaths in Canada. LYs and QALYs lost due to IMD would be 36,612 and 30,122, respectively (discounted: 4,238 and 3,633, respectively) (Table 2). Total national expected costs (discounted) would be $597.5 million, including $182 million in vaccination costs, $81 million in direct medical costs, and $335 million in indirect costs.

Adolescent vaccination with MCV-4 in place of MCV-C is projected to reduce the number of IMD cases by 1,826 (16%), cases of IMD sequelae by 267 (16%), and IMD deaths by 161 (13%). LYs and QALYs lost due to IMD would be reduced by 5,081 (14%) and 4,291 (14%), respectively (432 and 380 discounted, respectively). Total costs are projected to be reduced by $14 million (2%), reflecting increased vaccination costs of $32 million, which are offset by savings of $9 million in direct medical costs and savings of $37 million in indirect costs.

Compared with infant and adolescent vaccination with MCV-C, infant and adolescent vaccination with MCV-4 is projected to reduce the number of IMD cases by 4,401 (46%), cases of IMD sequelae by 629 (43%), and IMD deaths by 367 (35%). LYs and QALYs lost due to IMD would be reduced by 12,067 (38%) and 10,319 (40%), respectively (1,067 and 956 discounted, respectively). Total costs are projected to increase by $54 million (9%), reflecting increased...
vaccination costs of $172 million, which are only partly offset by savings of $24 million in
direct medical costs and savings of $93 million in indirect costs.

Compared with infant vaccination with MCV-C and adolescent vaccination with MCV-4,
MCV-4 for both infants and adolescents is projected to reduce the number of IMD cases by
2,575 (37%), cases of IMD sequelae by 362 (33%), and IMD deaths by 206 (25%). LYs and
QALYs lost due to IMD would be reduced by 6,986 (28%) and 6,028 (30%), respectively (635
and 576 discounted, respectively). Total costs are projected to increase by $68 million (10%),
reflecting increased vaccination costs of $140 million, which are only partly offset by savings of
$15 million in direct medical costs and savings of $57 million in indirect costs.

Because MCV-C/4 is projected to have lower costs and yield more QALYs than MCV-C/C,
MCV-C/4 is considered to be “dominant” versus MCV-C/C in the base case (Table 3). Because
MCV-C/4 dominates MCV-C/C, it is appropriate to compare MCV-4/4 vs MCV-C/4. The
cost-effectiveness of MCV-4/4 versus MCV-C/4 is projected to be $111,286 per QALY gained.
Based on WHO-CHOICE thresholds for cost-effectiveness [27], MCV-4/4 would be a cost-
effective use of healthcare resources since this amount falls within the range of 1–3 times the
Canadian GDP per capita [28].

Table 2. Expected lifetime clinical and economic outcomes under alternative strategies for vaccination against meningococcal disease in Canada.

| Clinical outcomes (mean, 95% CI) | MCV-C/C | MCV-C/4 | MCV-4/4 |
|--------------------------------|---------|---------|---------|
| No. of IMD cases               | 11,438 (2,030–41,092) | 9,612 (1,778–34,061) | 7,037 (999–27,653) |
| No. of IMD sequelae cases      | 1,715 (244–6,757) | 1,448 (207–5,934) | 1,086 (120–4,485) |
| No. of IMD deaths              | 1,195 (95–5,374) | 1,034 (82–4,620) | 828 (50–3,921) |
| Life-years Lost (vs. No IMD)   | 36,612 (3,899–141,891) | 31,531 (3,453–122,542) | 24,545 (2,024–101,965) |
| Not discounted                 | 36,612 (3,899–141,891) | 31,531 (3,453–122,542) | 24,545 (2,024–101,965) |
| Discounted                     | 4,238 (377–17,927) | 3,806 (347–16,148) | 3,171 (213–14,021) |
| QALYs lost (vs. No IMD)        | 30,122 (3,555–113,511) | 25,831 (3,079–96,592) | 19,803 (1,819–79,774) |
| Not discounted                 | 30,122 (3,555–113,511) | 25,831 (3,079–96,592) | 19,803 (1,819–79,774) |
| Discounted                     | 3,633 (365–14,462) | 3,253 (335–13,023) | 2,677 (208–11,287) |
| Costs, discounted, CAN$ millions (mean, 95% CI) | | | |
| Direct medical                 | | | |
| IMD                            | 36.2 (6.0–131.3) | 32.0 (5.6–109.6) | 25.2 (3.4–97.2) |
| Public health response         | 10.9 (1.9–38.6) | 9.7 (1.7–32.7) | 7.6 (1.0–27.5) |
| Sequelae                       | 33.5 (5.9–125.5) | 30.0 (5.3–110.8) | 23.6 (3.4–92.7) |
| Total direct medical costs     | 80.7 (14.4–290.9) | 71.7 (13.3–248.3) | 56.3 (8.3–213.5) |
| Vaccination                    | | | |
| Vaccine                        | 63.76 (63.76–63.76) | 95.40 (95.40–95.40) | 198.47 (198.47–198.47) |
| Administration                 | 117.25 (117.25–117.25) | 117.25 (117.25–117.25) | 154.23 (154.23–154.23) |
| Adverse events                 | 0.96 (0.96–0.96) | 0.96 (0.96–0.96) | 0.96 (0.96–0.96) |
| Total vaccination costs        | 181.97 (181.97–181.97) | 213.62 (213.62–213.62) | 353.66 (353.66–353.66) |
| Indirect                       | 334.9 (39.6–1,275.8) | 298.3 (35.8–1,117.9) | 241.6 (24.3–971.0) |
| Total                          | | | |
Estimates of the cost-effectiveness of MCV-C/4 were found to be relatively insensitive to changes in parameter values and assumptions, remaining dominant compared to MCV-C/C in all scenarios except when: (1) The IMD case rate was reduced by 50% (cost per QALY gained = $30,439); (2) the lower bound of the 95% confidence interval for vaccine effectiveness was used (cost per QALY gained = $54,592); (3) it was assumed there were no indirect effects with vaccination (cost per QALY gained = $137,303); and (4) prices were assumed to remain at current levels (cost per QALY gained = $181,404) (Table 4). Cost-effectiveness of MCV-4/4 vs MCV-C/4 was sensitive to changes in IMD incidence and case-fatality rates, vaccine effectiveness, the assumption of herd effects, the assumption of declining prices, the discount rate, and the model time frame. MCV-C/4 remained dominant compared with MCV-C/C even under the assumption that there would be no herd effects for five years after the change in the vaccination program. MCV-C/4 also remained dominant compared with MCV-C/C under the assumption that (1) vaccine prices would follow a step-function corresponding to 3 year tenders, (2) the average annual rate of decline in prices would be the same for MCV-C/4 as for MCV-C/C, and (3) prices would never fall below $4 per vaccine (the price that Sanofi currently charges UNICEF for MCV-4 and below which industrial capacity to manufacturer the vaccines might not be sustainable).

To further assess the sensitivity of model results to projections of the price of MCV-4, a threshold analysis was conducted to identify the price of MCV-4 at which the each of the vaccine strategies would be cost-effective given the threshold ICERs of $56,000 and $168,000 per QALY gained, respectively (1 and 3 times GDP per capita, respectively). In this analysis, the prices of both vaccines were held constant over time at their initial values. Assuming an ICER threshold of $56,000 per QALY gained, MCV-C/4 is projected to be cost-effective compared with MCV-C/C if the price of MCV-4 is less than or equal to $23.75. With an ICER threshold of $168,000 per QALY gained, MCV-C/4 is projected to be cost-effective compared with MCV-C/C if the price of MCV-4 is less than or equal to $30.60. These prices represent premiums of $10.63 and $17.48, respectively, over the estimated current price of MCV-C ($13.12). For the comparison of MCV-4/4 versus MCV/C/C, the prices at which the former is cost-
Table 4. Sensitivity analyses on cost-effectiveness (cost per QALY) of alternative strategies for vaccination against meningococcal disease in Canada.

|                      | MCV-C/4 vs MCV-C/C | MCV-C/C | MCV-4/MCV-C/C |
|----------------------|--------------------|---------|---------------|
|                      | ΔCosts (CANS Millions) | ΔQALYs | ICER (CAN $)  | ΔCosts (CANS Millions) | ΔQALYs | ICER (CAN $)  | ΔCosts (CANS Millions) | ΔQALYs | ICER (CAN $)  |
| Basecase             | -18.6              | 427     | Dominant      | 47.6               | 1,022          | Dominant      | 46,534              | 66.2   | 595           | 111,286          |
| IMD case rate        |                    |         |               |                    |                |               |                    |        |               |                  |
| Lower by 50%         | 6.5                | 214     | 30,439        | 109.6              | 511            | 214,526       | 103.1              | 297    | 346,704       |
| Higher by 50%        | -43.8              | 641     | Dominant      | -14.5              | 1,533          | Dominant      | 29.3               | 892    | 32,814        |
| IMD case-fatality rate |                  |         |               |                    |                |               |                    |        |               |                  |
| Lower by 40%         | -6.3               | 262     | Dominant      | 78.2               | 628            | 124,566       | 84.4               | 365    | 231,043       |
| Higher by 40%        | -31.0              | 592     | Dominant      | 16.9               | 1,416          | 11,953        | 48.0               | 824    | 58,187        |
| IMD sequelae rate    |                    |         |               |                    |                |               |                    |        |               |                  |
| Lower by 10%         | -17.5              | 426     | Dominant      | 50.2               | 1,019          | 49,320        | 67.8               | 593    | 114,332       |
| Higher by 10%        | -19.7              | 428     | Dominant      | 44.9               | 1,025          | 43,767        | 64.6               | 597    | 108,260       |
| Vaccine coverage     |                    |         |               |                    |                |               |                    |        |               |                  |
| Lower by 10% (81%/74%) | -16.8             | 377     | Dominant      | 40.7               | 913            | 44,541        | 57.5               | 536    | 107,220       |
| Higher by 10% (100%/94%) | -20.2             | 476     | Dominant      | 54.1               | 1,123          | 48,174        | 74.3               | 647    | 114,744       |
| Vaccine effectiveness in first year | | | | | | | | | |
| Lower bound of 95% CI (60.1%/39.0%) | 10.0              | 183     | 54,592        | 95.8               | 616            | 155,527       | 85.8               | 433    | 198,237       |
| Upper bound of 95% CI (98.3%/99.0%) | -21.7             | 454     | Dominant      | 40.3               | 1,083          | 37,220        | 62.0               | 630    | 98,553        |
| Waning of vaccine effectiveness | | | | | | | | | |
| Lower by 10% (7.1%/12.3%) | -21.9             | 456     | Dominant      | 43.3               | 1,062          | 40,781        | 65.2               | 605    | 107,743       |
| Higher by 10% (8.7%/15.0%) | -15.8             | 402     | Dominant      | 51.3               | 988            | 51,914        | 67.1               | 586    | 114,546       |
| Herd effects with MCV-4* | | | | | | | | | |
| Delayed by 5 years   | -9.5               | 354     | Dominant      | 64.7               | 882            | 73,302        | 74.2               | 528    | 140,368       |
| None                | 15.8               | 115     | 137,303       | 108.8              | 443            | 245,879       | 93.0               | 327    | 284,173       |
| Vaccine prices       |                    |         |               |                    |                |               |                    |        |               |                  |
| Stepped/equal rate of decline, $4 minimum | -10.1             | 427     | Dominant      | 82.0               | 1,022          | 80,283        | 92.1               | 595    | 154,857       |
| Remain at current levels | 77.5              | 427     | 181,404       | 403.3              | 1,022          | 394,627       | 325.8              | 595    | 547,726       |
| Utilities            |                    |         |               |                    |                |               |                    |        |               |                  |
| Lower by 25%         | -18.6              | 324     | Dominant      | 47.6               | 775            | 61,384        | 66.2               | 451    | 146,767       |
| Higher by 25%        | -18.6              | 485     | Dominant      | 47.6               | 1,147          | 41,476        | 66.2               | 662    | 100,023       |
| Medical Care Costs   |                    |         |               |                    |                |               |                    |        |               |                  |
| Lower by 25%         | -17.4              | 427     | Dominant      | 50.6               | 1,022          | 49,490        | 68.0               | 595    | 114,341       |
| Higher by 25%        | -19.8              | 427     | Dominant      | 44.5               | 1,022          | 43,578        | 64.4               | 595    | 108,232       |
| Two infant doses of MCV-C | -18.6             | 427     | Dominant      | -22.6              | 1,022          | Dominant      | -4.0               | 595    | Dominant      |
| Discount rates       |                    |         |               |                    |                |               |                    |        |               |                  |
| 0%                  | -240.7             | 4,787   | Dominant      | -288.2             | 10,935         | Dominant      | -47.6              | 6,148  | Dominant      |
| 3%                  | -49.8              | 946     | Dominant      | 4.0                | 2,216          | 1,817         | 53.8               | 1,269  | 42,396        |
| Modeling horizon     |                    |         |               |                    |                |               |                    |        |               |                  |

(Continued)
effective relative to the latter given ICER thresholds of $56,000 and $168,000 per QALY gained are $15.38 and $20.68, respectively (premiums of $2.26 and $7.56, respectively). The prices of MCV-4 at which MCV-4/4 is cost-effective compared with MCV-C/4 at these thresholds are $11.37 and $15.94, respectively. Thus, with a threshold ICER of $56,000 per QALY gained, the price of MCV-4 would need to be less than that of MCV-C for MCV-4/4 to be cost-effective compared with MCV-C/4.

In probabilistic sensitivity analyses, MCV-C/4 was more costly and more effective than MCV-C/C in 64% of the simulations and more effective and less costly (i.e., dominant) in 36% of the simulations. MCV-C/4 was cost-effective versus MCV-C/C in 47% of simulations at a threshold value of $56,000 per QALY gained (1 x GDP per capita) and in 65% of simulations at a threshold value of $168,000 per QALY gained (3 x GDP per capita). Compared with MCV-C/4, MCV-4/4 was more costly and more effective in 90% of simulations; it was more effective and less costly (i.e., dominant) in 10% of simulations. The probability that MCV-4/4 is cost-effective versus MCV-C/4 was 22% at a threshold value of $56,000 per QALY gained and 45% at a threshold value of $168,000 per QALY gained. Scatter plots and acceptability curves for all comparisons based on probabilistic sensitivity analyses are included in the Online Supplement.

### Discussion

Results of these analyses suggest that using MCV-4 in lieu of MCV-C for the adolescent booster in Canada, following universal meningococcal C vaccination in infancy, may be cost effective. Although replacing infant MCV-C vaccination with infant MCV-4 vaccination was cost-effective in base-case analyses, in probabilistic sensitivity analyses the probability that such a strategy would be cost effective was less than 50%.

In the only comparison that is the same in both our study and the aforementioned analysis by De Wals and colleagues (MCV-C/4 vs. MCV-C/C), estimated cost-effectiveness was substantially lower in our study (dominant) versus theirs ($113,206 per QALY gained) [7]. While there are a number of reasons for this difference, the most significant one is different vaccine prices used in the two analyses. Other sources of the difference are the modeling approach employed (prevalent plus successive birth cohorts in this study vs. prevalent cohort in De Wals), rates of incidence of IMD (lower in this study), and case-fatality rates (lower in this study).

Two important features of our analysis should be noted. First, we assumed in base-case analyses that the price of MCV-4 would approach that of MCV-C over time, based on exponential projections fit to historical data on from prices from prior tenders. While we believe this...
assumption to be reasonable, and consistent with recommendations for the conduct of economics evaluations in Canada and elsewhere, results are less favorable for MCV-4 vaccination if vaccine prices are assumed to remain at their current levels throughout the projection period.

Second, we estimated the indirect effects of MCV-4 vaccination on transmission using a modification of an approach first set forth by Bauch and colleagues [13, 14]. With this method, the benefits of herd effects are assumed to be the same across age groups. Nasopharyngeal carriage of *N. meningitidis* is highest in adolescents and young adults, who serve as reservoirs for transmission of the disease [29]. Accordingly, we may have overestimated the herd effects associated with infant MCV-4 vaccination. It also should be noted that although this general approach for approximating dynamic transmission models using a cohort model was developed for the evaluation of vaccination of influenza [13, 14], it should be generalizable to vaccination of other diseases.

Limitations of our study should be noted. First, because data on the epidemiology of IMD were not available for each province/territory separately, we used estimates of IMD rates and associated case-fatality rates based on data from all of Canada. To the extent that there are systematic differences across provinces/territories in disease epidemiology—as well as other parameters such as vaccine prices and medical costs—caution should be used in generalizing from the results of this study to a particular province/territory.

Second, initial effectiveness of infant vaccination against IMD was based on a single epidemiologic study of the vaccination experience in Quebec, Canada over a seven-year period of time [20]. This epidemiologic study employed the screening method to estimate vaccine effectiveness, which is less reliable than the case-control method. However, point estimates from this study are largely consistent with those from the various studies of the vaccination experience in the UK and Spain [30–32].

Third, because the Quebec study did not report effectiveness for adolescents, the initial effectiveness of adolescent vaccination (93%) was based on the estimate used by the ACIP of the U.S. CDC in their CEA of adolescent vaccination [21]. This estimate is conservative relative to the reported effectiveness of vaccination of children ≥2 years of age reported in the aforementioned Quebec study (97%) [20].

Fourth, absent comparable data on the effectiveness of MCV-4, it was assumed that effectiveness of this vaccine against all serogroups would be the same as that for MCV-C against serogroup C. However, data from randomized controlled trials suggest that immunogenicity of MCV-4 is non-inferior to MCV-C, and prior cost effectiveness evaluations have assumed similar effectiveness for MCV-4 and MCV-C [7, 33]. Further, results of sensitivity analyses suggest that MCV-C/4 may be cost-effective (cost per QALY gained less than one times GDP per capita) even under conservative assumptions regarding vaccine effectiveness. Data from a recent published data from Ontario reported that there was a significant decrease in the incidence of serogroup Y cases in the three years following the introduction of adolescent MCV-4 vaccination (19.8% reduction per year) [34]. It is difficult to draw firm conclusions from these data, however, as only three years of data following the initiation of the MCV4 program were available.

In England and Wales, the incidence of IMD has been declining for more than a decade, but meningococcal group W (MenW) cases have been increasing since 2009 due to rapid endemic expansion of a single clone belonging to cc11 that is associated with severe disease with unusual clinical presentations [35]. The analyses reported herein may be conservative as they did not consider the potential effects of future changes in underlying IMD incidence rates that might be associated with the potential transmission of such MenW clones to the Canadian setting.

Estimates of the costs of IMD were based on the best available published estimates, which may not be reflective of current treatment and costs. Future research may benefit from primary cost studies to document the current costs of IMD in Canada and elsewhere.
Projections of vaccines prices were based on a limited set of data and are therefore associated with substantial uncertainty. Given the small numbers of observations, we believe the assumption of a constant rate of decline in prices is not unreasonable and that fitting a more complicated price function with a variable rate of decline would be infeasible. While it is true that there are tender periods, and that in reality the curve will be a "step function", the precise dates of the future tenders are not known, and the use of a smooth function doesn’t materially impact the results. Also, while it is true that the price of MCV-4 is lower than MCV-3 by 20 years, the absolute difference beyond that point is not material (effectively representing an assumption of equal long-term prices). Last, in assessing cost-effectiveness, we use a threshold range from $56,000 to $168,000 per QALY gained, which corresponds to values for “highly cost-effective” and “cost-effective” in WHO-CHOICE guidelines (based on GDP per capita) [27, 28]. There are no recent published threshold values for evaluation of vaccines in Canada, and the applicability of the WHO thresholds, in particular the higher value of $168,000 per QALY gained, in Canada is debatable. Rocchi and colleagues reviewed the drug reimbursement recommendations of the advisory board of the Common Drug Review from September 2003 to March 2007, and reported that medications with a positive recommendation had cost-effectiveness ratios as high as $80,000 per QALY gained [36]. However, these recommendations were made a decade or more ago, and also take into consideration the quality of the clinical evidence, as well as the cost-effectiveness ratios, and therefore do not provide an unambiguous representation of the threshold. Using a threshold value of $100,000 per QALY gained, the estimated probability that MCV-C/4 would be cost-effective compared with MCV-C/C would be only 56%, and the base case estimate of the ICER for MCV-4/4 vs. MCV-C/4 would no longer be below the threshold.

In summary, results of this study suggest that if historical trends in vaccine prices continue, the use of MCV-4 rather than MCV-C in adolescents may be cost effective. Canadian provinces without MCV-4 programs should consider adoption of programs that include MCV-4 vaccination for adolescents.

**Supporting information**

S1 Table. Derivation of IMD incidence rates by serogroup.

S2 Table. Derivation of IMD incidence rates by age and serogroup.

S1 Fig. Scatter plot of difference in expected costs versus difference in expected quality-adjusted life-years for alternative strategies for vaccination against meningococcal disease in Canada.

S2 Fig. Acceptability curves for cost-effectiveness (cost per QALY) for alternative strategies for vaccination against meningococcal disease in Canada.

**Acknowledgments**

The authors thank the Canadian Public Health Agency which provided price information for prior tenders. The authors also thank Anoush Youssoufian and Vivian Ng for their assistance in the conduct of this study.
Author Contributions
Conceptualization: TED DW MA DN FPA EF JML AC.
Data curation: TED DW MA AC.
Formal analysis: TED DW MA AC.
Funding acquisition: TD AC.
Investigation: TED DW MA AC.
Methodology: TED DW MA DN FPA EF JML AC.
Project administration: TD DW AC.
Resources: TD DW AC.
Software: MA.
Supervision: TD DW AC.
Validation: TD DW MA FPA AC.
Visualization: TD DW MA FPA AC.
Writing – original draft: TD DW.
Writing – review & editing: TED DW MA DN FPA EF JML AC.

References
1. National Advisory Committee on Immunization (NACI). An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2009; 35(ACS-3):1–40. Epub 2009/04/30. PMID: 19400026
2. Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, et al. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Clin Infect Dis. 2014; 59(9):1208–15. Epub 2014/07/30. https://doi.org/10.1093/cid/ciu597 PMID: 25069868
3. Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, et al. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis. 2015; 60(8):e27–35. Epub 2015/01/22. https://doi.org/10.1093/cid/civ028 PMID: 25605282
4. Public Health Agency of Canada. Invasive Meningococcal Disease (IMD), 2012 [14 January 2014]. Available from: http://www.phac-aspc.gc.ca/im/vpd-mev/ meningococcal-eng.php.
5. Public Health Agency of Canada. Canadian Immunization Guide. 20 May 2015 [14 December 2015]. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php.
6. National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Update on Quadrivalent Meningococcal Vaccines available in Canada. April, 2015 [December 1, 2105]. Available from: http://publications.gc.ca/ collections/collection_2015/aspc-phac/HP40-125-2014-eng.pdf
7. De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine. 2007; 25(29):5433–40. Epub 2007/06/15. https://doi.org/10.1016/j.vaccine.2007.04.071 PMID: 17560695
8. Guidelines for the economic evaluation of health technologies: Canada [ 3rd Edition] Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006 [27 April 2017]. Available from: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf.
9. Statistics Canada. Population by year, by province and territory (Number). Ottawa, Ontario, Canada. Modified 25 November 2013 [21 February 2014]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/01/cst01/demo02a-eng.htm.
10. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008; 46(1):1–13. Epub 2008/01/04. https://doi.org/10.1086/524041 PMID: 18171206
11. Shepard CW, Ortega-Sanchez IR, Scott RD, 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005; 115(5):1220–32. Epub 2005/05/04. https://doi.org/10.1542/peds.2004-2514 PMID: 15867028

12. Pitman R, Fisman D, Zarić GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making. 2012; 32(5):712–21. Epub 2012/09/20. https://doi.org/10.1177/0272989X12454578 PMID: 22990086

13. Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making. 2009; 29(5):557–69. Epub 2009/07/17. https://doi.org/10.1177/0272989X09334419 PMID: 19605882

14. Van Vlaenderen I, Van Bellinghen LA, Meier G, Nautrup BP. An approximation of herd effect due to vaccinating children against seasonal influenza—a potential solution to the incorporation of indirect effects into static models. BMC Infect Dis. 2013; 13:25. Epub 2013/01/24. PubMed Central PMCID: PMC3570298. https://doi.org/10.1186/1471-2334-13-25 PMID: 23339290

15. Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006–2011. Canada Communicable Disease Report CCDR. 2014; 40(9).

16. Public Health Agency of Canada. Enhanced surveillance of invasive meningococcal disease in Canada: 1, January 2002–31, December 2003. [21 May 2014]. Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/dr3208a-eng.php.

17. Stovall SH, Schutze GE. Meningococcal infections in children from Arkansas. Pediatr Infect Dis J. 2002; 21(5):366–70. Epub 2002/08/02. PMID: 12150169

18. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001; 33(5):737–9. Epub 2001/07/31. https://doi.org/10.1086/322587 PMID: 11477523

19. Caro JJ, Moller J, Getisios D, Coudeville L, El-Hadi W, Chevat C, et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health. 2007; 7:130. Epub 2007/07/03. PubMed Central PMCID: PMC1925079. https://doi.org/10.1186/1471-2458-7-130 PMID: 17603880

20. De Wals P, Deceuninck G, Lefebvre B, Boullanne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J. 2011; 30(7):566–9. Epub 2011/02/18. https://doi.org/10.1097/INF.0b013e31820e638 PMID: 21326136

21. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meisner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62(RR-2):1–28. Epub 2013/03/22. PMID: 23515099

22. Public Health Ontario Partners for Health. Monthly Infectious Diseases Surveillance Report. Ontario, Canada. December 2013: 2(12): 1–20 [27 April 2017]. Available from: http://www.publichealthontario.ca/en/DataAndAnalytics/Documents/PHO_Monthly_Infectious_Diseases_Surveillance_Report_-_December_2013.pdf.

23. Novartis Vaccines and Diagnostics Inc. Product Monograph. Menveo®. Date of Preparation: November 2014. [17 October 2016]. Available from: http://ca.gsk.com/media/1204037/menveo-pm-23dec2014.pdf.

24. Sanofi Pasteur Limited. Product Monograph. Menactra®. Date of Revision: June 2012 [6 August 2014]. Available from: https://www.vaccineshoppecanada.com/document.cfm?file=menactra_e.pdf.

25. World Bank. Global Purchasing Power Parities and Real Expenditures. 2005 International Comparison Program. Washington, DC, USA [21 February 2014]. Available from: http://siteresources.worldbank.org/ICPINT/Resources/icp-final.pdf.

26. Statistics Canada. Consumer Price Index, health and personal care, by province (Canada) (table). Modified 23 January 2015 [13 September 2015]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/ecn161a-eng.htm.

27. World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). World Health Organization 2014. Available from: http://www.who.int/choice/costs/CER_thresholds/en/.

28. World Bank. GDP per capita (current US$). World Development Indicators. Washington, DC, USA. [5 June 2014]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.PD.

29. Bogaert D, Hermans PW, Boelen H, Sluijter M, Luijendijk A, Rumke HC, et al. Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. Clin Infect Dis. 2005; 40(6):899–902. Epub 2005/03/01. https://doi.org/10.1086/428351 PMID: 15756029

30. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009; 27 Suppl 2:B20–9. Epub 2009/05/30.
31. Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005; 23(32):4097–100. Epub 2005/05/24. https://doi.org/10.1016/j.vaccine.2005.03.045 PMID: 15908059

32. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004; 364(9431):365–7. Epub 2004/07/28. https://doi.org/10.1016/S0140-6736(04)16725-1 PMID: 15276396

33. Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W (1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One. 2013; 8(5):e65036. Epub 2013/06/07. PubMed Central PMCID: PMC3669019. https://doi.org/10.1371/journal.pone.0065036 PMID: 23741448

34. Wormsbecker AE, Wong K, Jamieson FB, Crowcroft NS, Deeks SL. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment. Vaccine. 2015; 33(42):5678–83. Epub 2015/08/25. https://doi.org/10.1016/j.vaccine.2015.08.023 PMID: 26299749

35. Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015; 60(4):578–85. Epub 2014/11/13. https://doi.org/10.1093/cid/ciu881 PMID: 25389259

36. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008; 11(4):771–83. Epub 2008/01/09. https://doi.org/10.1111/j.1524-4733.2007.00296.x PMID: 18179658